# US 2006/0069135 A1 · Benzimidazole derivatives and their use for modulating the gaba-a receptor complex

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069135 A1
- Document ID: US20060069135A1
- Status: Published application
- Kind: A1
- Application number: 10/546,437
- Filed: 2004-04-01
- Published: 2006-03-30
- Earliest claimed: 2003-04-03
- Inventors: Lene Teuber; Janus Larsen
- Web page: https://patentgrep.com/patent/US20060069135A1

## CPC

- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 409/10: linked by a carbon chain containing aromatic rings
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular for combating anxiety and related diseases.

## Claims

### Claim 1

A compound of general formula (I):
or an N-oxide thereof, or any of its isomers or any mixture of its isomers,
or a pharmaceutically acceptable salt thereof,
wherein
R represents hydroxyalkyl, alkoxyalkyl, cycloalkoxyalkyl, cycloalkylalkoxyalkyl, alkenyloxyalkyl, or alkynyloxyalkyl; and
R′ represents a 5-membered heterocyclic ring;
which heterocyclic ring may optionally be substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, amino, alkylamino, aminoalkyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, and alkynyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R represents hydroxymethyl, alkoxymethyl, or cycloalkylalkoxymethyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R represents 1-hydroxyethyl, 1-alkoxyethyl, 1-(cycloalkylalkoxy)ethyl, 1-(alkenyloxy)ethyl, or 1-(alkynyloxy)ethyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R represents 2-hydroxy-2-propyl, 2-alkoxy-2-propyl, or 2-(cycloalkylalkoxy)-2-propyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R′ represents imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, thiazolyl, pyrrolyl, or pyrrolidinyl.

### Claim 6 (depends on 1)

The compound of claim 1, which is
1-(3-(1-Imidazolyl)phenyl)-5-(methoxymethyl)benzimidazole;
1-(3-(1-Imidazolyl)phenyl)-5-(ethoxymethyl)benzimidazole;
1-(3-(1-Imidazolyl)phenyl)-5-(isopropoxymethyl)benzimidazole;
1-(3-(1-Imidazolyl)phenyl)-5-(propoxymethyl)benzimidazole;
1-(3-(1-Imidazolyl)phenyl)-5-(cyclopropylmethoxymethyl)benzimidazole;
1-(3-(1-Pyrazolyl)phenyl)-5-(methoxymethyl)benzimidazole;
1-(3-(1-Pyrazolyl)phenyl)-5-(hydroxymethyl)benzimidazole;
1-(3-(1-Pyrazolyl)phenyl)-5-(ethoxymethyl)benzimidazole;
1-(3-(1-Pyrazolyl)phenyl)-5-(isopropoxymethyl)benzimidazole;
1-(3-(1-Pyrazolyl)phenyl)-5-(propoxymethyl)benzimidazole;
1-(3-(1-Pyrazolyl)phenyl)-5-(cyclopropylmethoxymethyl)benzimidazole;
1-(3-(3-Furyl)phenyl)-5-(methoxymethyl)benzimidazole;
1-(3-(3-Furyl)phenyl)-5-(hydroxymethyl)benzimidazole;
1-(3-(3-Furyl)phenyl)-5-(ethoxymethyl)benzimidazole;
1-(3-(3-Furyl)phenyl)-5-(isopropoxymethyl)benzimidazole;
1-(3-(3-Furyl)phenyl)-5-(propoxymethyl)benzimidazole;
1-(3-(3-Furyl)phenyl)-5-(cyclopropylmethoxymethyl)benzimidazole;
1-(3-(2-Thienyl)phenyl)-5-(methoxymethyl)benzimidazole;
1-(3-(2-Thienyl)phenyl)-5-(hydroxymethyl)benzimidazole;
1-(3-(2-Thienyl)phenyl)-5-(ethoxymethyl)benzimidazole;
1-(3-(2-Thienyl)phenyl)-5-(isopropoxymethyl)benzimidazole;
1-(3-(2-Thienyl)phenyl)-5-(propoxymethyl)benzimidazole;
1-(3-(2-Thienyl)phenyl)-5-(cyclopropylmethoxymethyl)benzimidazole;
5-(1-Hydroxyethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-(Allyloxy)ethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-(Propargyloxy)ethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-Methoxyethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-Ethoxyethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-Propoxyethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-Isopropoxyethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-(Cyclopropylmethoxy)ethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(1-Hydroxyethyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole;
5-(1-Methoxyethyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole;
5-(1-Ethoxyethyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole;
5-(1-Propoxyethyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole;
5-(1-Isopropoxyethyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole;
5-(1-(Cyclopropylmethoxy)ethyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole;
5-(1-Hydroxyethyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(1-Methoxyethyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(1-Ethoxyethyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(1-Propoxyethyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(1-Isopropoxyethyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(1-(Cyclopropylmethoxy)ethyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(2-Hydroxy-2-propyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(2-Methoxy-2-propyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(2-Ethoxy-2-propyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(2-Propoxy-2-propyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(2-Isopropoxy-2-propyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(2-(Cyclopropylmethoxy)-2-propyl)-1-(3-(1-pyrrolidinyl)phenyl)benzimidazole;
5-(Hydroxymethyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole;
5-(Hydroxymethyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole;
5-(Hydroxymethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(Hydroxymethyl)-1-(3-(1-pyrrolyl)phenyl)benzimidazole;
5-(Methoxymethyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole;
5-(Methoxymethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(Ethoxymethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(Isopropoxymethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(Propoxymethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(Cyclopropylmethoxymethyl)-1-(3-(3-isoxazolyl)phenyl)benzimidazole;
5-(Methoxymethyl)-1-(3-(1-pyrrolyl)phenyl)benzimidazole;
5-(Ethoxymethyl)-1-(3-(1-pyrrolyl)phenyl)benzimidazole;
5-(Isopropoxymethyl)-1-(3-(1-pyrrolyl)phenyl)benzimidazole;
5-(Propoxymethyl)-1-(3-(1-pyrrolyl)phenyl)benzimidazole;
5-(Cyclopropylmethoxymethyl)-1-(3-(1-pyrrolyl)phenyl)benzimidazole;
5-(Ethoxymethyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole;
5-(Isopropoxymethyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole;
5-(Propoxymethyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole;
5-(Cyclopropylmethoxymethyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole;
or an N-oxide thereof, or any of its isomers or any mixture of its isomers,
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1, or an N-oxide thereof, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

### Claim 8 (depends on 1)

A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the GABAA receptor complex in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 1, or an N-oxide thereof, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The method according to claim 8, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the GABAA receptor complex in the central nervous system.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the disease, disorder or condition is anxiety disorders, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias, social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder; stress disorders, post-traumatic and acute stress disorder, sleep disorders, memory disorder, neuroses, convulsive disorders, epilepsy, febrile convulsions in children, migraine, depressive or bipolar disorders, single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and bipolar II manic disorders, cyclothymic disorder, psychotic disorders, including schizophrenia, neurodegeneration arising from cerebral ischemia, attention deficit hyperactivity disorder, pain, nociception, emesis, acute, delayed and anticipatory emesis, particular emesis induced by chemotherapy or radiation, motion sickness, post-operative nausea, vomiting, eating disorders, anorexia nervosa, bulimia nervosa, premenstrual syndrome, muscle spasm, spasticity, e.g. in paraplegic patients, the effects of substance abuse or dependency, alcohol withdrawal, cognitive disorders, Alzheimer's disease, or disorders of circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.

### Claim 11

(canceled)
